Opioid salts and formulations exhibiting anti-abuse and anti-dumping properties

A method of administering an active pharmaceutical comprising:

• providing a drug substance consisting of an organic acid salt of an opioid as said active pharmaceutical wherein said drug substance does not have a wt % released at 30 minutes in 0.1 N hydrochloric acid in USP water comprising 20% USP ethanol which is higher than in 0.1 N hydrochloric acid in USP water without ethanol
• forming a drug product comprising said drug substance suitable for achieving a therapeutic dose of said drug substance in a predetermined time
• wherein when administered said therapeutic dose is not exceeded by ingestion of alcohol at biological pH;
• wherein said drug substance is selected from the group consisting of:
• amorphous oxycodone pamoate characterized by a method selected from the group consisting of:
• a differential scanning calorimetery thermogram of FIG. 1;
• an FTIR of FIG. 2;
• and
• an X-ray diffraction diffractogram of FIG. 3;
• polymorphic oxycodone pamoate characterized by a method selected from the group consisting of:
• a differential scanning calorimetery thermogram of FIG. 4;
• an FTIR of FIG. 5;
• and
• an X-ray diffraction diffractogram of FIG. 6;
• polymorphic oxycodone pamoate characterized by a method selected from the group consisting of:
• a differential scanning calorimetery thermogram of FIG. 98;
• an FTIR of FIG. 99;
• and
• an X-ray diffraction diffractogram of FIG. 100;
• hydrocodone xinafoate characterized by a method selected from the group consisting of:
• a differential scanning calorimetery thermogram of FIG. 16;
• an FTIR of FIG. 17;
• and
• an X-ray diffraction diffractogram of FIG. 18;
• and
• amorphous hydromorphone pamoate characterized by a method selected from the group consisting of:
• a differential scanning calorimetery thermogram of FIG. 19;
• an FTIR of FIG. 20;
• and
• an X-ray diffraction diffractogram of FIG. 21.